Jun. 1 at 12:54 PM
$EWTX $43.01 +9.35 EXIT
$85.00
Holding long position at zero cost created by partial SELLS at profit.
UPDATE:
Co announces that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten and Edgewise's muscular dystrophy business for
$1.55 bln in upfront cash and up to
$1.1 bln in additional milestone payments, for aggregate potential consideration of up to
$2.65 bln.
The transaction meaningfully strengthens Edgewise's balance sheet, providing enhanced financial flexibility and sharpening the co's strategic focus on its cardiovascular pipeline.
Following the closing of the transaction, Edgewise will become a cardiovascular focused company, with a pipeline comprising EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003 for an undisclosed target. Co expects the transaction to close in 3Q26.
